Multipe is developed by Hormozgan University of Medical Sciences.

What development phase is Multipe in?

Multipe is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Multipe

Hormozgan University of Medical Sciences · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Multipe
Sponsor	Hormozgan University of Medical Sciences
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM (PHASE3)
Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome (PHASE2)
Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Multipe CI brief — competitive landscape report
Multipe updates RSS · CI watch RSS
Hormozgan University of Medical Sciences portfolio CI